Core Insights - The heart cryoablation system developed by Shenyang Pengyue Technology Co., Ltd. has been launched, marking a significant advancement in the integration of technological and industrial innovation in Liaoning Province [1][5] - This system addresses the global health challenge of atrial fibrillation, particularly persistent and long-term cases that typically require complex surgical interventions [1] - The innovative medical device has received approval from the National Medical Products Administration, filling a gap in the high-end medical equipment sector in China and providing new treatment pathways for patients with persistent atrial fibrillation [5] Group 1 - The heart cryoablation system is a benchmark achievement in cultivating the "low-temperature cryomedicine" industry chain in Liaoning Province [1] - The system utilizes core technologies such as "rapid cooling," "active rewarming," and "backside temperature feedback," featuring a dual gas circulation system with argon as the coolant and helium as the heat medium [1] - The development of this system involved collaboration between the founding team of Shenyang Pengyue Technology and Professor Wang Huishan's team from the Northern Theater Command General Hospital of the People's Liberation Army [1] Group 2 - The innovative medical device is specifically approved for the treatment of persistent atrial fibrillation in adult heart disease patients [5] - The system's unique features include active rewarming, vacuum insulation, and backside temperature feedback, which are pioneering technologies in the field [5] - The approval of this device represents a significant milestone in the domestic high-end medical equipment landscape, offering new diagnostic and treatment options for patients [5]

Core Insights - The first unit of the cardiac cryoablation system developed by Shenyang Pengyue Technology Co., Ltd. has been officially launched, marking a significant advancement in the treatment of persistent atrial fibrillation in adult heart disease patients [1] - This innovative medical device is the first of its kind internationally to feature active rewarming, vacuum insulation, and backside temperature feedback technologies, filling a gap in the domestic high-end medical equipment sector and breaking the technological monopoly of foreign manufacturers in the field of surgical treatment for atrial fibrillation [1] Company Developments - The Pengyue Technology cryoablation system has received approval from the National Medical Products Administration for innovative medical device registration, enabling precise ablation of myocardial cells while maximizing the protection of myocardial fiber skeletons and surrounding nerve blood vessels [1] - The product is seen as a benchmark achievement in promoting the deep integration of technological innovation and industrial innovation within the Shenyang-Fushun Reform and Innovation Demonstration Zone, contributing to the development of a low-temperature cryogenic medical industry chain [1] Industry Impact - The introduction of this product is expected to demonstrate significant value in promoting the high-end and clustered development of strategic emerging industries [1]

Core Viewpoint - The world's first cardiac cryoablation system has been launched in the Shenyang-Fu Reform and Innovation Demonstration Zone, marking a significant advancement in the treatment of persistent atrial fibrillation and breaking the long-standing foreign monopoly in this field [1][3]. Group 1: Product Development - The cardiac cryoablation system features innovative technologies such as active rewarming, vacuum insulation, and backside temperature feedback, specifically designed for the surgical treatment of persistent atrial fibrillation in adult patients [1][3]. - The product was developed through a collaboration between Shenyang Pengyue Technology and the team led by Professor Wang Huishan from the Northern Theater Command General Hospital, overcoming key technical challenges over nearly five years [3][4]. - The system includes both the cryoablation device and disposable sterile cryoablation probes, which have recently received approval from the National Medical Products Administration [3]. Group 2: Industry Impact - The successful launch of this product represents a significant breakthrough in the high-end medical equipment sector in China and serves as a model for integrating medical and engineering fields, as well as for exploring new paths in industry-academia-research applications [3]. - This innovation is expected to enhance the development of the "low-temperature cryogenic medicine" industry chain and contribute to the high-end, clustered development of strategic emerging industries in Liaoning [3][4]. - The widespread adoption of this system is anticipated to optimize and upgrade maze surgical pathways, providing a safer, more efficient, and controllable treatment option for patients with persistent atrial fibrillation [4].

Core Points - The article highlights the approval of two innovative medical devices by Pengyue Technology, specifically a cardiac cryoablation device and a disposable sterile cryoablation probe, which are recognized as national-level innovative medical devices [1][2] - The provincial drug regulatory authority has been actively supporting the innovation of medical devices, optimizing the review and approval processes to accelerate the transformation of innovative results [2][3] - The new cardiac cryoablation system is expected to provide a safer, more efficient, and controllable treatment option for patients with persistent atrial fibrillation, with clinical trial results showing an 80% effectiveness rate in preventing recurrence six months post-surgery [2][3] Company Summary - Pengyue Technology has successfully developed a cardiac cryoablation system that addresses the limitations of traditional treatment methods and significantly reduces patient treatment costs [3] - The company formed a collaborative team to apply argon-helium cryogenic technology to surgical treatments, overcoming challenges related to cooling speed and rewarming processes [2] - The new products are set to be applied clinically in December, marking a significant advancement in the medical device industry [3] Industry Summary - The medical device industry in China is experiencing rapid growth, with the market size surpassing one trillion yuan [3] - The provincial drug regulatory authority plans to deepen reforms in drug regulation and support high-quality development in the pharmaceutical industry, aiming to benefit more companies from the regulatory changes [3]